ClinicalTrials.gg
Active, not recruitingNCT06591286Updated Nov 18, 2026

Effects of Real-time Continuous Glucose Monitoring System on Hospital-to-home Transitional Blood Glucose Control

An interventional study of RT-CGM and SMBG in Diabetes Mellitus, Type 2, sponsored by Shanghai 6th People's Hospital. Active, not recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Shanghai 6th People's Hospital · Not applicable, Interventional, and Treatment

How we know

Updated Nov 18, 2026Now Active, not recruitingPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
150
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies in Diabetes Mellitus, Type 2 by Shanghai 6th People's Hospital — 6 open to participants now, 7 under way, none of them phase 3. Diabetes Mellitus, Type 2 · Shanghai 6th People's Hospital.

Started
2024
the only one that year
No phase
7 of 11
3 open now
Registered
4th of 11
by date

Among the 11 studies in Diabetes Mellitus, Type 2 by Shanghai 6th People's Hospital, this one is the only one that started in 2024, is one of 7 with no phase, and was the 4th registered.

Diabetes Mellitus, Type 2

10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

6 of the 11 studies in Diabetes Mellitus, Type 2 by Shanghai 6th People's Hospital are open now, in 1 country. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Diabetes Mellitus, Type 2 by Shanghai 6th People's Hospital, or all of them as a file.
02

Study summary

Glucose monitoring is an important part of self-management for patients with diabetes. The results of glucose monitoring not only help to assess the degree of glucose metabolism disorders in patients, but also help physicians to make clinical decisions and guide patients in self-management. Despite extensive efforts and advances in diabetes management during hospitalization, glucose control after patients is discharged home remains a challenge. This trial aims to explore the effect of real-time continuous glucose monitoring (RT-CGM) system compared to self-monitoring of blood glucose (SMBG) group on glucose and self-efficacy of type 2 diabetes patients treated with insulin after discharge from the hospital.

Read the detailed description

Glycemic management of patients with diabetes after discharge home is extremely challenging, especially for those requiring insulin therapy. The use of a real-time continuous glucose monitoring (RT-CGM) system may improve glycemic control and self-efficacy in patients with type 2 diabetes treated with insulin after discharge from the hospital.

One hundred and fifty insulin-treated adults with type 2 diabetes were randomly assigned to receive either RT-CGM or self-monitoring of blood glucose (SMBG) at hospital discharge for a 12-week monitoring intervention and a 36-week follow-up.

03

Conditions studied

  • Diabetes Mellitus, Type 2

Keywords

  • Continuous Glucose Monitoring
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. 18 years old ≤ age ≤ 80 years old.
  2. Type 2 diabetes admitted to Department of Endocrinology and Metabolism.
  3. 8% ≤ ≤ 12% in the last 1 month.
  4. Insulin therapy within 1 month of planned discharge from hospital.
  5. Frequency of self-monitoring of blood glucose \<4 times per week and no use of real-time continuous glucose monitoring system in the 3 months prior to hospitalisation.
  6. Willing and able to provide written and comply with the requirements of this study.

Exclusion criteria

Exclusion Criteria:

  1. Oral hormone therapy.
  2. Patients with acute complications of diabetes (including Diabetic ketoacidosis, hyperglycemia and hyperosmolality, Lactic acidosis)
  3. Patients with severe liver disease ( or glutamine aminotransferase exceeding more than three times the ).
  4. Patients with severe kidney injury or end-stage renal disease ( \< 30 mL/min/1.73 m2).
  5. Participants were unable to tolerate tape adhesive around sensor placement area, or with medically documented allergy towards the adhesive (glue) of plasters, or with serious skin diseases (e.g. psoriasis vulgaris, bacterial skin diseases) around sensor placement area.
  6. Mental condition rendering the subject unable to understand the nature, scope, and possible consequences of the study.
  7. Pregnant, breastfeeding, women of childbearing age who are unwilling to use during the study period.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
150 participants (estimated)

Study arms

  • Experimental
    Intervention group

    The intervention group (75 cases) will wear real-time CGM to monitor blood glucose for 12 weeks, followed by 36 weeks of follow-up.

    Device: RT-CGM

  • Other
    Control group

    The control group (75 cases) is self-monitored by traditional SMBG for 12 weeks at a frequency of no less than 4 times a week, followed by 36 weeks of follow-up.

    Device: SMBG

Interventions

  • DeviceRT-CGM

    This group of patients will wear RT-CGM for blood glucose monitoring for three months.

  • DeviceSMBG

    This group of patients will use a a fingertip glucose meter for blood glucose monitoring for three months, and the monitoring frequency was not less than 4 times per week.

06

What researchers measure

Primary outcomes

  1. Time in range (3.9~10.0mmol/L, %)

    Percentage of time within glucose level of 3.9-10.0 mmol/L (70-180 mg/dL) measured by CGM.

    Time frame: 12 weeks

Secondary outcomes

  1. HbA1c (%)

    Glycated hemoglobin (%)

    Time frame: 4weeks, 8weeks, 12 weeks, 24weeks, 48weeks

  2. Time in range (3.9~10.0mmol/L, %)

    Percentage of time within glucose level of 3.9-10.0 mmol/L (70-180 mg/dL) measured by CGM.

    Time frame: 4weeks, 8weeks, 24weeks, 48 weeks

  3. Time above range (>10.0mmol/L, %)

    Percentage of time above glucose level of 10.0 mmol/L (180 mg/dL) measured by CGM.

    Time frame: 4weeks, 8weeks, 12 weeks, 24weeks, 48weeks

  4. Time below range (<3.9mmol/L, %)

    Percentage of time below glucose level of 3.9 mmol/L (70 mg/dL) measured by CGM.

    Time frame: 4weeks, 8weeks, 12 weeks, 24weeks, 48weeks

  5. Coefficient of variation (CV)

    Standard deviation divided by mean glucose level measured by CGM.

    Time frame: 4weeks, 8weeks, 12 weeks, 24weeks, 48weeks

  6. Standard deviation (SD)

    Standard deviation of blood glucose measurements during CGM.

    Time frame: 4weeks, 8weeks, 12 weeks, 24weeks, 48weeks

  7. Mean amplitude of glycemic excursions (MAGE)

    Mean amplitude of glycemic excursions (MAGE) is the average value of all amplitude of glycemic excursions.

    Time frame: 4weeks, 8weeks, 12 weeks, 24weeks, 48weeks

  8. Diabetes management self-efficacy

    The Chinese version of Diabetes Management Self-efficacy Scale (DMSES) is used to evaluate the patients' self-efficacy

    Time frame: 4weeks, 8weeks, 12 weeks, 24weeks, 48weeks

  9. Diabetes Self Care Activities

    The Chinese version of Summary of Diabetes Self Care Activities (SDSCA) is used to evaluate the patients' self-efficacy

    Time frame: 4weeks, 8weeks, 12 weeks, 24weeks, 48weeks

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2024 to primary completion in Mar 2026, 16 months.

Of 2,078 non-industry interventional studies with no phase under Diabetes Mellitus, Type 2, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 40. This study's 16 months is below that.

Counting every sponsor, half of 2,255 studies reached it within 21 months; a quarter within 10 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 7, 2024
First posted
Sep 19, 2024
StartActual
Oct 25, 2024
Primary completionActual
Mar 23, 2026
CompletionEst.
Sep 30, 2027
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Nov 18, 2026
Sites
1 site added, 1 site removed
Show site
  • Shanghai 6th People's Hospital · Shanghai, China
Show 1 removed
  • Shanghai 6th People's Hospital · Shanghai, China
Nov 18, 2026
Primary completion
Mar 10, 2026→Mar 23, 2026 (actual)
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    Recruiting→Active, not recruiting
    1 site added, 1 site removed
    Show site
    • Shanghai 6th People's Hospital · Shanghai, China
    Show 1 removed
    • Shanghai 6th People's Hospital · Shanghai, China
    Primary completion Mar 10, 2026→Mar 23, 2026 (now actual)
    + 2 other changes: verification date and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06591286
Lead sponsor
Shanghai 6th People's Hospital
Responsible party
Jian Zhou (Professor, Chief Physician, Deputy Director, Department of Endocrinology and Metabolism, Shanghai 6th People's Hospital) — Principal investigator
First posted
Sep 19, 2024
Start date
Oct 25, 2024
Primary completion
Mar 23, 2026
Completion
Sep 30, 2027 (estimated)
Last update
Nov 18, 2026

Study contacts

Jian Zhou, Dr.
principal investigator · Shanghai 6th People's Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion